[Annual progress in tobacco medicine in 2023].

Smoking is one of the major risk factors for several chronic non-infectious diseases, including chronic respiratory diseases, cancers, cardiovascular diseases, and diabetes, which has become a major public health issue in China. Tobacco control is proven to be the most effective and cost-effective strategy to reduce the risk of smoking-related disease and premature death. From October 2022 to September 2023, several high quality studies on tobacco medicine have been published. This review systematically summarizes the representative studies in terms of epidemiological study, clinical study, mechanism study, and tobacco control progress. These studies further highlight the concept that "tobacco smoking is the main evil for disease and tobacco control is the main good for disease prevention", which will promote the development of tobacco medicine in China.吸烟是多种慢性呼吸疾病、恶性肿瘤、心脑血管疾病和糖尿病等慢性非传染性疾病的“共性”危险因素，是我国当前最重要的公共卫生问题之一，而控烟是疾病防控最有效且符合成本效益的干预措施。2022年10月至2023年9月间，烟草病学领域发表了大量高质量研究，本综述选择了其中具有代表性的成果，从流行病学研究、临床研究、机制研究、控烟工作进展等方面进行综述，以期更多人更加深刻认识到“吸烟为致病之首恶，控烟为防病之首善”的理念。.